KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Capital Expenditures (2019 - 2025)

GoodRx Holdings' Capital Expenditures history spans 7 years, with the latest figure at -$52.4 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 177.01% year-over-year to -$52.4 million; the TTM value through Dec 2025 reached $3.5 million, down 94.91%, while the annual FY2025 figure was $3.5 million, 94.91% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$52.4 million at GoodRx Holdings, down from $16.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $68.0 million in Q4 2024 and bottomed at -$52.4 million in Q4 2025.
  • The 5-year median for Capital Expenditures is $12.3 million (2022), against an average of $7.8 million.
  • The largest annual shift saw Capital Expenditures soared 3484.55% in 2022 before it plummeted 368.27% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $26.1 million in 2021, then plummeted by 223.04% to -$32.1 million in 2022, then surged by 141.86% to $13.5 million in 2023, then skyrocketed by 405.68% to $68.0 million in 2024, then plummeted by 177.01% to -$52.4 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Capital Expenditures are -$52.4 million (Q4 2025), $16.3 million (Q3 2025), and $39.5 million (Q2 2025).